摘要
目的探讨多西他赛为主的联合化疗方案治疗转移性乳腺癌的临床价值。方法 30例转移性乳腺癌患者随机分为观察组和对照组,观察组采用多西他赛+表阿霉素+CTX(环磷酰胺)治疗,对照组采用表阿霉素+CTX治疗,比较两组的临床疗效和不良反应情况。结果观察组的临床治疗有效率(66.67%)、临床受益率(86.67%)均高于对照组(P<0.05)。结论多西他赛为主的联合化疗方案治疗转移性乳腺癌,临床疗效满意,没有增加不良反应,临床受益反应良好。
Objective To discussed the value of docetaxel-based combineded chemotherapy in the treatment of metastatic breast cancer.Methods 30 cases of metastatic breast cancer patients were randomly divided into observation group and control group. Observation group were treated with docetaxel-based-epirubicin＋CTX, control group were treated with epirubicin＋CTX, clinical curative effect and adverse reactions in two groups were compared. Results The clinical total effective rate （66.67%）, clinical beneficial rate （86.67%）of observation group were obviously higher than that of control group （P〈0.05）. Conclusion Docetaxel-based combination chemotherapy is effective for metastatic breast cancer. There is no increase in adverse reaction, the clinical benefit response is good.
出处
《中国继续医学教育》
2016年第29期144-146,共3页
China Continuing Medical Education
关键词
转移性乳腺癌
多西他赛
化学治疗
Metastatic breast cancer, Docetaxel, Chemotherapy
